Loading...
Confirmation of the Cardiac Safety of PGF(2α) Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments
OBE022, a new orally active prostaglandin F(2α) receptor antagonist (OBE022) with myometrial selectivity is being developed to reduce uterine contractions during preterm labor. This first‐in‐human study evaluated the effect of OBE022 following multiple doses on the QT interval in 23 healthy postmeno...
Na minha lista:
| Udgivet i: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6221050/ https://ncbi.nlm.nih.gov/pubmed/29489066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.447 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|